Patents by Inventor Kenneth M. MEYERS

Kenneth M. MEYERS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20240262822
    Abstract: Isoquinolinone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 8, 2024
    Inventors: Taekyu Lee, Kevin B. Teuscher, Somenath Chowdhury, Jianhua Tian, Kenneth M. Meyers, Stephen W. Fesik
  • WDR5 inhibitors and modulators
    Patent number: 11999716
    Abstract: Isoquinolinone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: June 4, 2024
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Joseph R. Alvarado, Jianhua Tian, Kenneth M. Meyers, Changho Han, Jonathan J. Mills, Kevin B. Teuscher, Shaun R. Stauffer, Stephen W. Fesik, Rocco D. Gogliotti
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20230026466
    Abstract: Isoquinolmone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Application
    Filed: November 8, 2020
    Publication date: January 26, 2023
    Inventors: Taekyu Lee, Kevin B. Teuscher, Jianhua Tian, Kenneth M. Meyers, Somenath Chowdhury, Stephen W. Fesik
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20230012362
    Abstract: Isoquinolinone compounds and derivatives inhibit WDRS and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Application
    Filed: October 24, 2019
    Publication date: January 12, 2023
    Inventors: Taekyu Lee, Joseph R. Alvarado, Jianhua Tian, Kenneth M. Meyers, Changho Han, Jonathan J. Mills, Kevin B. Teuscher, Shaun R. Stauffer, Stephen W. Fesik
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20220242849
    Abstract: Quinazolin-4(3H)-one, 2,3-dihydroquinazolin-4(1H)-one, 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one, and 3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Application
    Filed: June 4, 2020
    Publication date: August 4, 2022
    Inventors: Taekyu Lee, Changho Han, Jonathan J. Mills, Kevin B. Teuscher, Jianhua Tian, Kenneth M. Meyers, Somenath Chowdhury, Stephen W. Fesik
  • Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases
    Patent number: 10858342
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jennifer Burke, Zhidong Chen, Derek Cogan, John Lord, Daniel Richard Marshall, Bryan P. McKibben, Kenneth M. Meyers, Yunlong Zhang
  • WDR5 inhibitors and modulators
    Patent number: 10844044
    Abstract: Described are imino-azacycle-benzamide compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: November 24, 2020
    Assignee: Vanderbilt University
    Inventors: Joseph R. Alvarado, Shaun R. Stauffer, Rocco D. Gogliotti, Changho Han, Kenneth M. Meyers, Jianhua Tian, Jonathan D. Macdonald, Stephen W. Fesik, Taekyu Lee
  • WDR5-MLL1 inhibitors and modulators
    Patent number: 10807959
    Abstract: Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: October 20, 2020
    Assignee: Vanderbilt University
    Inventors: Rocco D. Gogliotti, Shaun R. Stauffer, KyuOk Jeon, James M. Salovich, Jonathan D. Macdonald, Jonathan J. Mills, Kenneth M. Meyers, Joseph R. Alvarado, Changho Han, Stephen W. Fesik, Taekyu Lee
  • BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASES, CARDIOVASCULAR DISEASES AND FIBROTIC DISEASES
    Publication number: 20200109131
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: June 21, 2017
    Publication date: April 9, 2020
    Inventors: Michael BALESTRA, Jennifer BURKE, Zhidong CHEN, Derek COGAN, John LORD, Daniel Richard MARSHALL, Bryan P. MCKIBBEN, Kenneth M. MEYERS, Yunlong ZHANG
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20200102288
    Abstract: Described are imino-azacycle-benzamide compounds compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Application
    Filed: June 14, 2019
    Publication date: April 2, 2020
    Inventors: Joseph R. Alvarado, Shaun R. Stauffer, Rocco D. Gogliotti, Changho Han, Kenneth M. Meyers, Jianhua Tian, Jonathan D. Macdonald, Stephen W. Fesik, Taekyu Lee
  • WDR5-MLL1 INHIBITORS AND MODULATORS
    Publication number: 20200055824
    Abstract: Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.
    Type: Application
    Filed: August 16, 2019
    Publication date: February 20, 2020
    Inventors: Rocco D. Gogliotti, Shaun R. Stauffer, KyuOk Jeon, James M. Salovich, Jonathan D. Macdonald, Jonathan J. Mills, Kenneth M. Meyers, Joseph R. Alvarado, Changho Han, Stephen W. Fesik, Taekyu Lee
  • Aldosterone synthase inhibitors
    Patent number: 10131642
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jörg M. Bentzien, Jennifer Burke, Derek Cogan, Xin Guo, Keith R. Hornberger, John Lord, Kenneth M. Meyers, Zhaoming Xiong, Maolin Yu, Zhonghua Zhang
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20180312475
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: January 28, 2016
    Publication date: November 1, 2018
    Inventors: Michael BALESTRA, Jörg M. BENTZIEN, Jennifer BURKE, Derek COGAN, Xin GUO, Keith R. HORNBERGER, John LORD, Kenneth M. MEYERS, Zhaoming XIONG, Maolin YU, Zhonghua ZHANG